Moberg Pharma AB (publ) (MOB) Q2 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Moberg Pharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.183 -- 00:00:05.752 Hello everyone and thank you for joining the Moberg Pharma Q3 Earnings Call. 00:00:05.752 -- 00:00:08.636 My name is Becky and I will be your operator today. 00:00:08.636 -- 00:00:12.783 During the presentation, you can register a question by pressing star followed by one 00:00:12.783 -- 00:00:17.611 on your keypad. If you change your mind, please press star followed by two. 00:00:17.611 -- 00:00:22.859 I will now hand over to your host, CEO of Moberg Pharma, Anna Young, to begin. 00:00:22.859 -- 00:00:25.279 Please go ahead. 00:00:26.004 -- 00:00:30.688 Thank you and good afternoon everyone. Thank you for joining our Q3 earnings call today. 00:00:30.688 -- 00:00:35.833 I'm Anna Jung, CEO of Mobut Pharma, and I also have our VP of Finance, Mark Beveridge, 00:00:35.833 -- 00:00:41.659 with me today. We're happy to present our Q3 report that you can find on our webpage. 00:00:41.659 -- 00:00:46.163 There you can also find a PowerPoint presentation that I'll base this call upon. 00:00:46.163 -- 00:00:50.247 And this call will be recorded and uploaded to our webpage. 00:00:50.247 -- 00:00:54.892 In today's call, I'll be providing an overview of our performance this quarter, discussing 00:00:54.892 -- 00:01:00.483 key developments in our business, and highlighting important strategic milestones. 00:01:00.786 -- 00:01:05.293 Starting with the positive developments, I'm proud to report that Teclara continues to 00:01:05.293 -- 00:01:10.221 lead the market in Sweden. The launch has exceeded our expectations, making a strong 00:01:10.221 -- 00:01:14.507 and successful market entry that has established our presence effectively. 00:01:14.507 -- 00:01:19.735 Year-to-date, we captured 30% of the market share by value and 25% by units 00:01:19.7...